Paul E. Sax
Contributing Editor at NEJM Journal Watch
Editor-in-Chief/Clinical Director at Clinical Infection in Practice
Harvard/Brigham Infectious Diseases doctor, writer, @CIDJournal editor, educator. Prefer baseball to football, pizza to sushi, dogs to cats, Beatles to Stones.
Articles
-
1 week ago |
blogs.jwatch.org | Paul E. Sax
Those of us who follow infectious diseases and vaccine science closely (OK, obsessively) know that the FDA's Center for Biologics Evaluation and Research (CBER) plays an enormous role in public health. Vaccines, gene therapies, monoclonal antibodies, blood products - all pass through CBER on their path to approval.
-
2 weeks ago |
blogs.jwatch.org | Paul E. Sax
First-year ID fellows this time of year bring a lot to inpatient consult rotations. Years of high-volume inpatient care have sharpened their clinical instincts, and at this point they have an impressive fund of ID knowledge.
-
4 weeks ago |
blogs.jwatch.org | Paul E. Sax
For those who do hospital-based patient care, the significance of Staphylococcus aureus bacteremia (SAB) cannot be overstated. It's one of the most frequent reasons for infectious disease consultations - and for good reason: when mismanaged or complicated, it can lead to high morbidity, a myriad of complications, and a disturbingly high mortality rate.
-
1 month ago |
blogs.jwatch.org | Paul E. Sax
Back in prehistoric times, many ID doctors and microbiologists would gather each fall at a meeting to review the latest antimicrobial clinical trials and promising "bug-drug" studies of novel compounds in development. The meeting was called the Interscience Conference on Antimicrobial Agents and Chemotherapy, abbreviated ICAAC. There were a bunch of problems with ICAAC. First, everyone associates "chemotherapy" with cancer treatment, which of course this wasn't.
-
1 month ago |
blogs.jwatch.org | Paul E. Sax
Imagine you're birdwatching in the Costa Rican rainforest, Merlin app in hand. A flash of iridescent blue catches your eye. You scan the canopy and whisper excitedly:Look, it's the elusive Blujepa! A rare sighting!No, not a real bird, but Blujepa is the brand name of gepotidacin, something rarer - and arguably more exciting - than a tropical bird, at least to us ID geeks: a brand new antibiotic class for treatment of uncomplicated urinary tract infections.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 57K
- Tweets
- 5K
- DMs Open
- No
The SNAP trial may finally resolve some of the longest-running debates in SAB management (cefazolin vs semi-synthetic PCN? Is PCN really active vs PSSA?). Congrats to @syctong @Josh_S_Davis, and the global team who made this ambitious trial happen. https://t.co/n8ZXrqrRM6
Remember ICAAC? Bad name, weirder pronunciation ("ick-kack"), and a classic case study in conference identity crisis. A look back—and where the big ID trials land now, which is @ESCMID Global. Following closely! #IDSky https://t.co/jAeZmRO3m4
Latest post on a new antibiotic, gepotidacin, which has a novel mechanism of action, is the first new drug for uncomplicated UTIs in decades, and has a brand name that sounds a lot like a tropical bird. Plus some digressions on prog rock, for no reason. https://t.co/CLkO65yo3O
